Prognostic Value and Echocardiographic Determinants of Plasma Myeloperoxidase Levels in Chronic Heart Failure
- 19 June 2007
- journal article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 49 (24), 2364-2370
- https://doi.org/10.1016/j.jacc.2007.02.053
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failureAmerican Heart Journal, 2006
- Myeloperoxidase-Generated Oxidants Modulate Left Ventricular Remodeling but Not Infarct Size After Myocardial InfarctionCirculation, 2005
- Role of Oxidative-Nitrosative Stress and Downstream Pathways in Various Forms of Cardiomyopathy and Heart FailureCurrent Vascular Pharmacology, 2005
- Myeloperoxidase and Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart FailureCirculation, 2005
- Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severityJournal of Cardiac Failure, 2004
- Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic functionJournal of the American College of Cardiology, 2004
- Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stressHeart, 2003
- Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial InfarctionThe Journal of Experimental Medicine, 2003
- Nitric Oxide Modulates the Catalytic Activity of MyeloperoxidaseOnline Journal of Public Health Informatics, 2000